Galectin-10 is a member of the lectin family and one of the most abundant cytoplasmic
proteins in human eosinophils. Except for some myeloid leukemia cells, basophils, and …

abstract Biologics targeting the molecules associated with type 2 inflammation have
significantly improved the outcomes of patients with severe eosinophilic asthma and chronic …

Background Dupilumab is an anti‐T2‐inflammatory biological registered for chronic
rhinosinusitis (CRS) with nasal polyps (CRSwNP), indicated by integrated CRS‐care …

Background Dupilumab, a monoclonal anti‐IL‐4Rα antibody, is approved for several type 2
mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-
neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil …

Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are
limited in previous studies. Herein, we report two cases in which EP developed subsequent …

Bronchial asthma is characterized by airway inflammation, airway hyperresponsiveness,
and reversible airway obstruction. Eosinophils contribute to the pathogenesis of airway …

Background Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare disease
characterized by pulmonary radiological alterations, peripheral eosinophilia, and …

Eosinophilic pneumonia (EP) is a rare but noteworthy adverse effect linked to dupilumab, an
interleukin-4 (IL-4) and IL-13 inhibitor used in the managing atopic diseases. The underlying …

A 63‐year‐old woman with refractory atopic dermatitis started treatment with dupilumab. She
developed a cough 4 days later, sputum, and a slight fever 2 weeks later. Laboratory test …